Introduction
The neurotrophin brain-derived neurotrophic factor (BDNF) and its cognate neurotrophin receptor, TrkB, regulate many key brain functions involved in survival, neurogenesis, neuroplasticity, and learning and memory, among others (Cowansage et al., 2010; Leal et al., 2015; Peng et al., 2005) , Alzheimer's disease (AD) (Allen et al., 2011; Erickson et al., 2010; Ginsberg et al., 2019; Tanila, 2017) , and Huntington's disease (Autry and Monteggia, 2012; Zuccato and Cattaneo, 2009 ). Downregulation of Bdnf occurs in the hippocampus in end-stage AD (Alvarez et al., 2014; Garzon et al., 2002; Holsinger et al., 2000; Michalski et al., 2015; Murray et al., 1994; Phillips et al., 1991; Sen et al., 2017) , and those who died with a clinical diagnosis of MCI (Ginsberg et al., 2019) . In contrast, TrkB, both the extracellular domain (ECD) and tyrosine kinase (TK) forms, display significant downregulation in MCI and AD compared to those with no cognitive impairment (NCI) in CA1 pyramidal neurons and regional hippocampal dissections (Ginsberg et al., 2019) . Moreover, downregulation of TrkB ECD and TrkB TK significantly correlate with the abundance of neuritic plaques (NPs) and neurofibrillary tangles (NFTs), but not diffuse plaques (DPs) (Ginsberg et al., 2019) . Specifically, decreased TrkB levels are associated with increased hippocampal CA1 NP load, entorhinal cortex NFTs, and hippocampal CA1 NFTs (Ginsberg et al., 2019) . These correlative findings indicate Bdnf and/or TrkB dysfunction may associate with AD lesions during the progression of dementia, suggesting boosting BDNF-TrkB signaling as a potential therapeutic approach. This association remains an under investigated area in the AD field.
To determine whether Bdnf and TrkB expression levels are associated with AD neuropathology during the progression of AD, we applied negative binomial (NB) regressions to expression profile data accrued from a homogeneous population of CA1 pyramidal neurons and regional hippocampal dissections. Postmortem samples were obtained from subjects enrolled in the Rush Religious Orders Study (RROS), a longitudinal clinical pathological study of aging and dementia in retired Catholic clergy (Bennett and Launer, 2012; Bennett et al., 2002 Bennett et al., , 2012 Malek-Ahmadi et al., 2018; Mufson et al., 1999 Mufson et al., , 2012 Mufson et al., , 2016a . Each RROS participant received an annual detailed premortem clinical and postmortem neuropathological evaluation, enabling an assessment of Bdnf and TrkB levels in relation to entorhinal cortex and hippocampal NPs, NFTs, and DPs in the same cases.
Materials and methods

Clinical evaluation
All subjects came to autopsy with no coexisting clinical conditions contributing to cognitive impairment as judged by the examining neurologist and were not receiving anticholinesterase drug therapy. A more detailed description of the RROS cohort has been published previously (Bennett and Launer, 2012; Bennett et al., 2002; Mufson et al., 2000 Mufson et al., , 2002b Mufson et al., , 2016a Mufson et al., , 2016b . Premortem cognitive assessments were performed each year prior to death. Memory tests consisted of the East Boston Memory immediate and delayed recall, Logical Memory immediate and delayed story recall, Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Word List Memory immediate and delayed recall, and CERAD Word List Recognition. A board-certified neurologist with expertise in the evaluation of the elderly, and blinded to age, sex, race/ethnicity, and clinical data other than occupation, education, and information about sensory or motor deficits, used these results to summarize impairments in each of the five cognitive domains. At consensus conferences, neurologists and neuropsychologists reviewed clinical and medical records and family interviews before assigning a final clinical diagnosis. Subjects were clinically categorized as NCI, MCI insufficient to meet criteria for dementia, and AD according to the criteria that our group and others have reported in a large number of clinical pathology studies that used tissue from the RROS (Bennett and Launer, 2012; Bennett et al., 2002; Mufson et al., 2000 Mufson et al., , 2002b Mufson et al., , 2016a Mufson et al., , 2016b . Within the RROS cohort the MCI designation continues to be attributed to subjects with impaired cognitive testing who did not display frank dementia (Abner et al., 2017; Han et al., 2012 Han et al., , 2015 . Case selection for this study was performed in association with the Neuropathology Core of the RROS (Oveisgharan et al., 2018; Yu et al., 2019) , similar to our previously published studies (Ginsberg et al., 2019; Malek-Ahmadi et al., 2016 Mufson et al., 2016a Mufson et al., , 2016b .
Neuropathological evaluation
For microarray and neuropathological analyses, hippocampal tissue were immersion-fixed in 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.2, paraffin embedded, and cut at 6 μm thickness (Ginsberg et al., 2010 (Ginsberg et al., , 2019 . A series of tissue sections for each case were prepared for neuropathological evaluation including visualization and quantitation of NPs, DPs, and NFTs using a modified Bielschowsky silver stain, Thioflavine-S, and antibodies directed against amyloid-β peptide (Aβ; 4G8, monoclonal, BioLegend, San Diego, CA) and tau (PHF1, monoclonal, a gift of Dr. Peter Davies, Hofstra Northwell School of Medicine) (Ginsberg et al., 2010; Malek-Ahmadi et al., 2016; Mufson et al., 2000 Mufson et al., , 2002a . Amyloid plaque load and NFT burden were determined by counting the total number of NPs, DPs, and NFTs per subject using a modified Bielschowsky silver stain in one square mm area (100× magnification) from the entorhinal cortex and hippocampal CA1 region (Ginsberg et al., 2019; Malek-Ahmadi et al., 2016; Mufson et al., 2016b) .
All cases were evaluated by a board-certified neuropathologist blinded to clinical diagnosis. Designation of "normal", "possible AD", "probable AD", or "definite AD" was based on estimation of neuritic plaque density, as established by CERAD (Mirra et al., 1991) . Each case also received a Braak score using NFT pathology staging (Braak and Braak, 1991) . RROS cases also received NIA-Reagan diagnosis of Alzheimer's disease and NINCDS-ADRDA designations Dubois et al., 2007; Hyman and Trojanowski, 1997) . Exclusion criteria include hippocampal sclerosis, Lewy body disease, Parkinson's disease, and identified strokes. Apolipoprotein E (ApoE) allele status was determined as described previously (Counts et al., 2007; Mufson et al., 2000 Mufson et al., , 2016b .
Bdnf and TrkB gene expression in CA1 pyramidal neurons and regional hippocampal dissections
The procedures for single population and regional hippocampal microarray analysis on human postmortem tissue have been described in detail previously (Ginsberg et al., 2006 (Ginsberg et al., , 2010 (Ginsberg et al., , 2012 (Ginsberg et al., , 2019 Tiernan et al., 2016) . Briefly, individual CA1 pyramidal neurons were microaspirated via laser capture microdissection (Arcturus PixCell IIe, Ther-moFisher Scientific, South San Francisco, CA). Fifty CA1 pyramidal neurons were captured for population analysis. After accruing CA1 neurons, the remaining tissue containing the entorhinal cortex, CA1, CA2, and CA3 sectors, dentate gyrus, and subicular complex medial to the rhinal sulcus was microaspirated in total as described previously (Ginsberg et al., 2012 (Ginsberg et al., , 2019 . RNAs were amplified by the terminal continuation (TC) RNA amplification method developed as previously described (Alldred et al., 2008 (Alldred et al., , 2009 Che and Ginsberg, 2004; Ginsberg, 2005 Ginsberg, , 2008 Ginsberg, , 2014 . The TC RNA amplification protocol is available at http://cdr.rfmh.org/pages/ginsberglabpage.html. Microaspirated samples were homogenized in 100 μl of Trizol (ThermoFisher Scientific, Waltham, MA), extracted with chloroform, and precipitated utilizing isopropanol (Alldred et al., 2009) . RNAs were reverse transcribed in the presence of poly d(T) primer (100 ng/μl) and TC primer (100 ng/μl) in 1X first strand buffer (ThermoFisher Scientific), 2 μg of linear acrylamide (Applied Biosystems, Foster City, CA), 10 mM dNTPs, 100 μM dithiothreitol (DTT), 20 U of SuperRNase Inhibitor (Applied Biosystems) and 200 U of reverse transcriptase (Superscript III, Ther-moFisher Scientific). Single stranded cDNAs were digested and placed in a thermal cycler in a solution consisting of 10 mM Tris (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , and 10 U RNase H (ThermoFisher Scientific) in a final volume of 100 μl. The thermal cycler program ran as follows: RNase H digestion step at 37°C, 30 min; denaturation step 95°C, 3 min; primer re-annealing step 60°C, 5 min (Alldred et al., 2009; Che and Ginsberg, 2004) . Samples were purified by column filtration (MilliporeSigma, Billerica, MA). Hybridization probes were synthesized by in vitro transcription using 33 P incorporation in 40 mM Tris (pH 7.5), 6 mM MgCl 2 , 10 mM NaCl, 2 mM spermidine, 10 mM DTT, 2.5 mM ATP, GTP and CTP, 100 μM of cold UTP, 20 U of RNase inhibitor, 2 KU of T7 RNA polymerase (LGC, Middleton, WI), and 120 μCi of 33 P -UTP (Perkin-Elmer, Boston, MA) (Alldred et al., 2009; Ginsberg, 2008) . The reaction was performed at 37°C for 4 h. Radiolabeled TC RNA probes were hybridized to custom-designed cDNA arrays without further purification.
Custom-designed cDNA array platforms and hybridization
Arrays were prehybridized (2 h) and hybridized (12 h) in a solution consisting of 6X saline-sodium phosphate-ethylenediaminetetraacetic acid (SSPE), 5X Denhardt's solution, 50% formamide, 0.1% sodium dodecyl sulfate (SDS), and denatured salmon sperm DNA (200 μg/ml) at 42°C in a rotisserie oven (Che and Ginsberg, 2004; Ginsberg, 2008) . Following hybridization, arrays were washed sequentially in 2X SSC/ 0.1% SDS, 1X SSC/0.1% SDS and 0.5X SSC/0.1% SDS for 15 min each at 37°C. Arrays were placed in a phosphor screen for 24 h and developed on a phosphor imager (GE Healthcare, Piscataway, NJ). All array phosphor images were adjusted to the same brightness and contrast levels for data acquisition (Alldred et al., 2012 (Alldred et al., , 2015 (Alldred et al., , 2018 .
Hybridization signal intensity was determined utilizing ImageQuant software (GE Healthcare). Each array was compared to negative control arrays without any starting RNA. Bdnf and TrkB expression was expressed as a ratio of the total hybridization signal intensity of the array (Ginsberg et al., 2000 (Ginsberg et al., , 2006 (Ginsberg et al., , 2010 (Ginsberg et al., , 2012 (Ginsberg et al., , 2019 .
Statistical analysis
For demographic and neuropathological variables, the Chi-square test was used to analyze categorical variables. The Kruskall-Wallis test was used to analyze group differences for continuous and count variables. The Conover-Inman test was used to test groupwise comparisons.
Expression levels of Bdnf and TrkB with AD neuropathology associations were examined using NB regression models, employing Bdnf or TrkB as predictor variables with NPs, DPs, and NFTs (entorhinal cortex for Model 1 and hippocampal CA1 for Model 2) as the outcome variable. An interaction term was included for Bdnf/TrkB and APOE ε4 carrier status. Age, gender, and APOE ε4 carrier status were included as covariates in all models.
NB regression models were used due to significantly skewed distributions for entorhinal cortex and hippocampal CA1 NPs, DPs, and NFTs in CA1 pyramidal neurons and regional hippocampal dissections ( Fig. 1) , which were analogous to NB distributions (Berk and MacDonald, 2008) . Additional justification for the use of NB regression models (Kim and Kriebel, 2009 ) is presented, as the variance values for each of the pathology measures were substantially greater than their means. For CA1 pyramidal neurons, mean entorhinal cortex NFT counts were 22.03 with a variance of 359.48 and mean hippocampal CA1 sector NFT counts were 23.08 with a variance of 615.54. For regional hippocampal dissections, mean entorhinal cortex NFT counts were 16.55 with a variance of 275.23 and mean hippocampal CA1 sector NFT counts were 22.82 with a variance of 606.14. Accordingly, entorhinal cortex and hippocampal CA1 NP, DP, and NFT data were tested to determine whether they followed a NB distribution (p > 0.05). NB model fits were assessed by testing residual deviance values and their associated degrees of freedom in the chisquare distribution where (p > 0.05) indicated good model fit (Tjur, 1998) . Statistical analyses were performed using the 'glm.nb' function in R 3.4.0 using the "MASS" package while model fit was determined by using the 'pchisq' function. NB distribution testing for NP, DP, and NFT data was performed using the 'goodfit' function in the "vcd" package {The R Project for Statistical Computing, www.r-project.org; (Vose, 2008)}. Statistical significance was set at (p ≤ 0.05).
Results
Demographic and neuropathological characteristics for dissections of CA1 pyramidal neurons across groups
Demographic and neuropathological characteristics for each group are shown in Table 1 . Age at death and years of education were not significantly different (p = 0.68, p = 0.19, respectively). No significant difference in the proportions of males and females was found (p = 0.33). The APOE ε4 allele was more prevalent in AD relative to NCI and MCI (p < 0.001). Postmortem interval (PMI) and brain weight at autopsy were not significantly different (p = 0.45, p = 0.23, respectively).
In entorhinal cortex, NCI displayed significantly lower NP counts relative to MCI (p = 0.01) and AD (p < 0.001), whereas MCI and AD were not significantly different (p = 0.11). MCI had significantly higher DP counts than NCI (p < 0.001). However, differences between NCI and AD as well MCI and AD were not statistically significant (p = 0.10, p = 0.30, respectively). NCI had significantly lower entorhinal cortex NFTs relative to MCI (p = 0.03) and AD (p < 0.001). MCI and AD displayed similar levels of NFT pathology (p = 0.08).
Hippocampal CA1 region NP counts were significantly different between all three clinical groups (NCI < MCI, p < 0.001; NCI < AD, p = 0.001; MCI < AD, p = 0.04). For CA1 region DPs, NCI displayed significantly lower number compared to MCI (p = 0.01) and AD (p < 0.001). MCI and AD were not significantly different (p = 0.28). For CA1 NFTs, AD had significantly greater counts than NCI (p < 0.001) and MCI (p = 0.02). NCI and MCI were not significantly different (p = 0.08).
Braak stage was not significantly different between clinical groups (p = 0.06). Stage I: NCI = 23%, MCI = 13%, AD = 0%; Stage II: NCI = 15%, MCI = 0%, AD = 11%; Stage III: NCI = 23%, MCI = 13%, AD = 0%; Stage IV: NCI = 39%, MCI = 40%, AD = 22%; Stage V: NCI = 0%, MCI = 33%, AD = 67%. The CERAD criteria Definite AD classification was more prevalent in MCI and AD relative to NCI (p = 0.05). The NIA-Reagan High Likelihood classification was most prevalent in AD (p < 0.001) while the Intermediate Likelihood classification was most prevalent in MCI.
Relation of single population CA1 pyramidal neuron Bdnf and TrkB expression levels with AD pathology
Bdnf expression within a homogeneous population of CA1 pyramidal neurons was not significantly different between clinical groups (p = 0.09; Fig. 2A ). A separate analysis of NCI and MCI demonstrated significant downregulation (p = 0.03). TrkB expression showed significant downregulation with disease progression (NCI > MCI, p < 0.001; NCI > AD, p < 0.001; MCI = AD, p = 0.50; Fig. 2B ). Both Bdnf and TrkB were not significantly associated with PMI (β = −0.06, SE = 0.10, p = 0.57) and (β = 0.00, SE = 0.02, p = 0.95), respectively.
Single population CA1 pyramidal neuron Bdnf expression was not significantly associated with entorhinal cortex NPs (β = 0.03, SE = 0.11, p = 0.79), DPs (β = −0.06, SE = 0.11, p = 0.62), or NFTs (β = −0.05, SE = 0.08, p = 0.31) ( Table 2) . Interactions for APOE ε4 status and Bdnf were not statistically significant for NPs (β = −0.10, SE = 0.15, p = 0.53), DPs (β = 0.07, SE = 0.16, p = 0.65), or NFTs (β = −0.08, SE = 0.08, p = 0.31). Model fit was deemed to be good for the NP (p = 0.14), DP (p = 0.13), and NFT (p = 0.13) models. Bdnf was significantly associated with CA1 NPs (β = −0.30, SE = 0.12, p = 0.008; Fig. 3A ), but not with DPs (β = −0.07, SE = 0.11, p = 0.53) or NFTs (β = 0.04, SE = 0.07, p = 0.54) ( Table 2) . Interactions for APOE ε4 status and Bdnf for CA1 regional pathology were not statistically significant for NPs (β = 0.27, SE = 0.16, p = 0.09), DPs (β = −0.23, SE = 0.16, p = 0.15), or NFTs (β = −0.16, SE = 0.10, p = 0.11). Model fit was deemed to be good for all models (NPs: p = 0.14, DPs: p = 0.23, NFTs: p = 0.09).
Single population CA1 neuron TrkB expression was not associated with entorhinal cortex NPs (β = −0.43, SE = 0.27, p = 0.11) or NFTs (β = −1.02, SE = 0.52, p = 0.10), but showed a significant association with DPs (β = −1.37, SE = 0.54, p = 0.02) ( Fig. 3B and Table 3 ). Model fit was deemed to be good for all models (NPs: p = 0.13, DPs: p = 0.14, NFTs: p = 0.14). For the CA1 analyses, TrkB was significantly associated with NPs (β = −1.18, SE = 0.50, p = 0.02; Fig. 3C ) but not DPs (β = −1.10, SE = 0.63, p = 0.08) or NFTs (β = −0.13, SE = 0.35, p = 0.71) ( Table 3) . The CA1 models all demonstrated good fit (NPs: p = 0.11, DPs: p = 0.30, NFTs: p = 0.09). , and neurofibrillary tangles (NFTs) for homogeneous CA1 pyramidal neurons (A-F) and regional hippocampal dissections (G-L). Individual histograms indicate the distributions for NP, DP, and NFT counts are heavily skewed toward lower values. Since these count data are the outcome variables, negative binomial (NB) regression models were used in order to obtain valid estimates of Bdnf and TrkB associations with NP, DP, and NFT counts.
Demographic and neuropathological characteristics for regional hippocampal dissections
Demographic and neuropathological characteristics for each group are shown in Table 4 . Age at death and years of education were not significantly different across groups examined (p = 0.18, p = 0.27, respectively). The proportions of male and female subjects was not statistically different (p = 0.74). The APOE ε4 allele was more prevalent in MCI and AD relative to NCI (p = 0.03). PMI and brain weight at autopsy were not significantly different (p = 0.54, p = 0.14, respectively). Braak stage was significantly different between clinical groups (p = 0.02). NCI cases had lower Braak stages relative to MCI and AD. Stage I: NCI = 23%, MCI = 10%, AD = 0%; Stage II: NCI = 31%, MCI = 0%, AD = 10%; Stage III: NCI = 15%, MCI = 10%, AD = 0%; Stage IV: NCI = 31%, MCI = 60%, AD = 30%; Stage V: NCI = 0%, MCI = 20%, AD = 60%. A CERAD diagnosis of Definite AD classification was more prevalent in MCI and AD relative to NCI (p = 0.05). The NIA-Reagan High Likelihood classification was most prevalent in AD (p < 0.001).
Significantly greater entorhinal cortex NP pathology was observed in AD relative to both NCI (p < 0.001) and MCI (p = 0.02). NCI and MCI were not significantly different (p = 0.17). Entorhinal cortex DPs were significantly greater in MCI compared to NCI (p = 0.01). No significant difference in DPs were found between NCI and AD (p = 0.14) as well as MCI and AD (p = 0.29). Entorhinal cortex NFTs were significantly lower in NCI compared to MCI (p = 0.03) and AD (p < 0.001). NFT pathology was similar between MCI and AD (p = 0.08). Both Bdnf and TrkB were not significantly associated with PMI (β = 0.05, SE = 0.05, p = 0.31) and (β = 0.06, SE = 0.04, p = 0.12), respectively. CA1 regional NPs were significantly greater in AD than NCI (p < 0.001) while MCI had significantly greater CA1 regional NP neuropathology compared to NCI (p = 0.02). MCI and AD were not significantly different (p = 0.14). CA1 regional DPs were not significantly different between groups (p = 0.18). CA1 NFTs showed group differences that were similar to that seen in the entorhinal cortex (NCI < MCI, p = 0.01; NCI < AD, p < 0.001; MCI = AD, p = 0.15).
Regional hippocampal dissection Bdnf and TrkB expression with AD pathology
Downregulation of hippocampal Bdnf was found between NCI and MCI (p < 0.001) while upregulation was observed between MCI and AD groups (p = 0.01) (Fig. 4A ). Downregulation of hippocampal TrkB was found between NCI and MCI (p < 0.001) and NCI and AD (p < 0.001) ( Fig. 4B ). No significant difference in TrkB expression was found between MCI and AD (p = 0.27).
Among entorhinal cortex pathology measures, hippocampal Bdnf was a significant predictor of NPs (β = −0.35, SE = 0.16, p = 0.02; Fig. 5A ), but not DPs (β = −0.21, SE = 0.17, p = 0.38) or NFTs (β = −0.04, SE = 0.09, p = 0.70) ( Table 5 ). Bdnf interactions with APOE ε4 carrier status were not significant for NPs (β = 0.27, SE = 0.24, p = 0.25), DPs (β = 0.23, SE = 0.27, p = 0.38), or NFTs (β = −0.09, SE = 0.14, p = 0.54). Entorhinal cortex pathology models for Bdnf all demonstrated good fit (NPs: p = 0.19, DPs: p = 0.15, NFTs: p = 0.11). For CA1 region pathology measures, Bdnf was not a significant predictor of NPs (β = 0.09, SE = 0.18, p = 0.64), DPs (β = −0.16, SE = 0.22, p = 0.45) or NFTs (β = −0.10, SE = 0.11, p = .35) ( Table 5 ). Bdnf interactions with APOE ε4 carrier status were not significant for NPs (β = −0.18, SE = 0.28, p = 0.51), DPs (β = 0.28, SE = 0.32, p = 0.37), or NFTs (β = −0.08, SE = 0.17, p = 0.64). Each CA1 pathology model demonstrated good fit (NPs: p = 0.18, DPs: p = 0.37, NFTs: p = 0.10).
Using hippocampal TrkB as a predictor of entorhinal cortex pathology, a significant association was found for NFTs (β = −0.26, SE = 0.10, p = 0.04; Fig. 5B ), but not DPs (β = −0.26, SE = 0.21, p = 0.22) or NPs (β = −0.22, SE = 0.21, p = 0.29) ( Table 6 ). TrkB and APOE ε4 carrier status associations were not significant for NPs (β = 0.05, SE = 0.37, p = 0.89), DPs (β = 0.05, SE = 0.37, p = 0.88), or NFTs (β = 0.00, SE = 0.19, p = 0.99). Entorhinal cortex pathology models for TrkB demonstrated good fit (NPs: p = 0.20, DPs: p = 0.15, NFTs: p = 0.12). For CA1 region pathology measures, TrkB was significantly associated with NPs (β = −0.58, SE = 0.19, p = 0.006; Fig. 5C ), but not DPs (β = −0.31, SE = 0.27, p = 0.26) or NFTs (β = −0.26, SE = 0.12, p = 0.08) ( Table 6 ). TrkB interactions with APOE ε4 carrier status were not significant for NPs (β = 0.48, SE = 0.39, p = 0.22), DPs (β = 0.08, SE = 0.42, p = 0.85), or NFTs (β = −0.28, SE = 0.22, p = 0.21). CA1 regional pathology models for TrkB all demonstrated good fit (NPs: p = 0.21, DPs: p = 0.35, NFTs: p = 0.11).
Discussion
The present investigation assessed associations between Bdnf and TrkB expression and NPs, DPs, and NFTs within a homogeneous population of CA1 pyramidal neurons as well as regional hippocampal dissections using postmortem tissues. The NB model using regional hippocampal entorhinal cortex NPs as an outcome measure demonstrates that downregulation of Bdnf is independently associated with increased regional entorhinal cortex NPs. A parallel observation was found with TrkB and entorhinal cortex NFTs. Specifically, downregulation of TrkB is independently associated with increased entorhinal cortex NFTs. These novel results suggest dysfunctional Fig. 2. A. Boxplots illustrating clinical group differences within homogeneous CA1 pyramidal neurons for Bdnf. Bdnf expression was not significantly different between the clinical groups (p = 0.09). A separate analysis yielded a significant downregulation in MCI compared to NCI (p = 0.03). B. Boxplots illustrating downregulation of TrkB during the progression of dementia within homogeneous CA1 pyramidal neurons. TrkB expression showed significant group differences where expression decreased with disease progression (NCI > MCI, p < 0.001; NCI > AD, p < 0.001; MCI = AD, p = 0.50).
hippocampal neurotrophin signaling, namely BDNF and its cognate receptor TrkB, is associated with, and may possibly be upstream of entorhinal cortex NPs and NFTs, early sites of AD pathology. Perhaps ameliorating BDNF/TrkB signaling deficits, especially within the entorhinal cortex and hippocampus, may potentially abrogate the formation of NP and NFT pathology. Although this hypothesis is conjectural, the power of this timely study is that it is an attempt at teasing apart a spatio-temporal association between neuronal transcript expression and AD pathology that can be validated or rejected in representative model systems. In this scenario, findings derived from human disease dictates what to assess in model systems, and not vice versa.
Significance of the possible temporal sequence of BDNF/TrkB deficits preceding neuropathology lies in its therapeutic potential. Several research laboratories, including our group, hypothesize deficits in BDNF signaling leads to selective vulnerability of specific neuronal populations, including hippocampal CA1 pyramidal neurons and cholinergic basal forebrain neurons of the nucleus basalis of Meynert (Erickson et al., 2010; Ginsberg et al., 2006 Ginsberg et al., , 2010 Ginsberg et al., , 2011 Ginsberg et al., , 2012 Ginsberg et al., , 2019 Mufson et al., 2007a Mufson et al., , 2007b Peng et al., 2005; Tanila, 2017) . Restoration of BDNF/TrkB signaling, either through neurotrophin delivery (Mitra et al., 2019; Nagahara et al., 2009 Nagahara et al., , 2013 , transactivation of the TrkB receptor, or activation of downstream pathways (Mitre et al., 2017; Rajagopal et al., 2004; Skaper, 2008) may provide neuroprotection by targeting mechanisms of neuroplasticity as well as preventing and/or attenuating amyloid and tau pathology Mufson et al., 2007a Mufson et al., , 2007b Mufson et al., , 2015 Nagahara et al., 2009) .
The association(s) between BDNF signaling and the cascades that lead to plaque and tangle formation are likely not unidirectional. Rather, a growing number of studies using relevant AD animal and cellular models suggests amyloid-β precursor protein (APP) and its metabolites, including amyloid-β peptide (Aβ) downregulates BDNF expression and BDNF-TrkB retrograde trafficking (Garzon and Fahnestock, 2007; Peng et al., 2009; Poon et al., 2011 Poon et al., , 2013 , possibly Fig. 3 . Association of Bdnf and TrkB expression in homogeneous CA1 pyramidal neurons with hippocampal CA1 region neuritic plaques and entorhinal cortex diffuse plaques. A. A significant inverse association was found between Bdnf expression and hippocampal CA1 region neuritic plaques by clinical group (β = −0.30, SE = 0.12, p = 0.008). B. A significant inverse association was found between TrkB expression and entorhinal cortex diffuse plaques by clinical group (β = −1.37, SE = 0.54, p = 0.02). C. A significant inverse association was found between TrkB expression and hippocampal CA1 region neuritic plaques by clinical group (β = −1.18, SE = 0.50, p = 0.02).
through cyclic adenosine monophosphate response element binding protein transcriptional downregulation (Rosa and Fahnestock, 2015) . Alternatively, loss of BDNF leads to changes in synaptic protein levels (Mariga et al., 2015) , cleavage and metabolism of APP (Matrone et al., 2008) and tau (Corsetti et al., 2008) . Since exogenous delivery of BDNF ameliorates synaptic as well as learning and memory deficits in primate and rodent AD models Iwasaki et al., 2012; Nagahara et al., 2009 Nagahara et al., , 2013 , extensive development has gone into devising BDNF brain delivery methods (Jiang et al., 2018; Mitra et al., 2019) . Moreover, increased tau pathology has been related to a depletion of BDNF signaling through the glucocorticoid receptor pathway (Arango-Lievano et al., 2016) . Tau overexpression decreases BDNF signaling in cellular and mouse models of AD and in tauopathy (Mazzaro et al., 2016; Rosa et al., 2016) . A defective BDNF response, likely through NMDA receptor signaling, has also been observed in a mouse model of tauopathy (Burnouf et al., 2013) . The present postmortem human tissue findings suggest multiple levels of regulation exist between neurotrophin signaling and amyloid and tau pathology that merit further investigation in both well-characterized clinical pathological cohorts of human subjects during the progression of dementia as well as in animal and cellular models that enable temporal sequences and mechanistic interactions to be elucidated. Similar to evaluations of NCI subjects with low-and high-AD pathology (Malek-Ahmadi et al., 2016 ) that failed to reveal correlations between DPs and cognitive decline, we found Bdnf and TrkB were not associated with DP load. However, CA1 TrkB showed a significant inverse association with entorhinal cortex DPs. The present dataset also lends support to the contention that NPs are the salient plaque species related to the pathogenesis of dementia, while DPs are more likely to be bystanders in disease progression (Dickson, 2009; Ginsberg et al., 2019; Malek-Ahmadi et al., 2018 Mufson et al., 2016a) .
This study provides proof-of-concept that individual transcripts within a functional gene ontology group (e.g., neurotrophins and neurotrophin receptors) can be used to predict (or to be an outcome measure) associated with AD neuropathology. Future studies evaluating other potential drivers of NPs and NFTs, such as endosomal-lysosomal Fig. 4 . A. Boxplots illustrating clinical group differences within regional hippocampal dissections for Bdnf. Significant downregulation of Bdnf was found between NCI and MCI (p < 0.001) while significant upregulation was observed between MCI and AD (p = 0.01). B. Boxplots illustrating clinical group differences within regional hippocampal dissections for TrkB. Significant downregulation was found for TrkB during the progression of dementia as MCI (p < 0.001) and AD (p < 0.001) displayed significantly less expression than NCI. No significant difference in TrkB expression was found between MCI and AD (p = 0.27).
2015; Mitra et al., 2019; Nagahara et al., 2009 Nagahara et al., , 2013 Rosa et al., 2016) are warranted based on our findings derived from bona fide human disease. Another caveat is the number of subjects relative to the number Fig. 5 . Association of Bdnf and TrkB expression in regional hippocampal dissections with entorhinal cortex neuritic plaques, entorhinal cortex neurofibrillary tangles, and hippocampal CA1 region neuritic plaques. A. A significant inverse association was found between Bdnf expression and entorhinal cortex neuritic plaques by clinical group (β = −0.35, SE = 0.16, p = 0.02). B. A significant inverse association was found between TrkB expression and entorhinal cortex neurofibrillary tangles by clinical group (β = −0.26, SE = 0.10, p = 0.04). C. A significant inverse association was found between TrkB expression and hippocampal CA1 neuritic plaques by clinical group (β = −0.58, SE = 0.19, p = 0.006). of predictors in the NB regression analyses. All of the NB models we employed contained five predictor variables (four main effect and one interaction), which by some standards, is too many for the sample sizes used in this study. Although the statistical convention that ten subjects per independent variable is ideal to provide valid estimates, studies have revealed that as few as two subjects per covariate can provide adequate estimates for regression models (Austin and Steyerberg, 2015) . Nonetheless, careful consideration was given to the selection of covariates and interaction terms used in the models to account for biologically relevant factors. In addition, goodness of fit assessments for each model indicated our data met the underlying assumptions of NB distribution. Therefore, we contend these models accurately support relationships between Bdnf and TrkB expression and NP/NFT pathology.
In summary, NB regression models were employed to infer Bdnf and TrkB within homogenous CA1 pyramidal neurons and heterogeneous hippocampal complex dissections in relation to NP, NFT, and DP pathology. Based upon our findings, we propose that BDNF signaling defects may be upstream of classic AD lesions. This does not preclude the possibility that amyloid and tau cascades impinge upon BDNF and TrkB regulation as part of a reciprocal regulatory loop exacerbating neurodegenerative pathology and serve as a node or hub for therapeutic intervention.
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